Develops small-molecule drug candidates for people with age-related degenerative diseases of the brain and retina, including Alzheimer’s disease and dementia with Lewy bodies.
10-K for FY2025, filed Mar 26, 2026We are a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics…View ↗
Our lead product candidate, zervimesine, also known as CT1812, is an orally delivered, small molecule designed to protect neuronal synapses…View ↗
The Company research also produced evidence that zervimesine prevents the binding of ɑ-synuclein to neurons, rescuing cellular function…View ↗
No revenue reported yet.
10-K for FY2024, filed Mar 20, 2025
10-Q for Q3 FY2026, filed Nov 5, 2026
−$4.1MView ↗
Focus on DLB psychosis
The latest report prioritizes developing zervimesine for dementia with Lewy bodies psychosis; the earlier report described evaluating it as a disease-modifying treatment for dementia with Lewy bodies.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 26, 2026We are evaluating CT1812 in a 120-patient Phase 2 COG1201 SHIMMER clinical trial to investigate the potential for CT1812’s use as a…View ↗
Prioritize development of zervimeinse for DLB psychosis. We intend to advance zervimesine for the treatment of DLB psychosis. Results from…View ↗
Geographic atrophy study ended
The earlier report planned a clinical study for geographic atrophy secondary to dry age-related macular degeneration; the latest report says that study was concluded.
10-K for FY2022, filed Mar 23, 2023 10-K for FY2025, filed Mar 26, 2026Based on proteomic evidence generated from the Company’s clinical programs in Alzheimer’s disease and supported by in vitro findings, the…View ↗
Loading...